Andrew L. Hopkins
Andrew L. Hopkins
Professor of Medicinal Informatics, University of Dundee
Verified email at - Homepage
Cited by
Cited by
How many drug targets are there?
JP Overington, B Al-Lazikani, AL Hopkins
Nature reviews Drug discovery 5 (12), 993-996, 2006
The druggable genome
AL Hopkins, CR Groom
Nature reviews Drug discovery 1 (9), 727-730, 2002
Network pharmacology: the next paradigm in drug discovery
AL Hopkins
Nature Chemical Biology 4 (11), 682-690, 2008
Ligand efficiency: a useful metric for lead selection.
AL Hopkins, CR Groom, A Alex
Drug discovery today 9 (10), 430, 2004
Navigating chemical space for biology and medicine
C Lipinski, A Hopkins
Nature 432 (7019), 855-861, 2004
Global mapping of pharmacological space
GV Paolini, RHB Shapland, WP van Hoorn, JS Mason, AL Hopkins
Nature biotechnology 24 (7), 805-815, 2006
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM KeserŁ, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
Quantifying the chemical beauty of drugs
GR Bickerton, GV Paolini, J Besnard, S Muresan, AL Hopkins
Nature chemistry 4 (2), 90-98, 2012
Network pharmacology
AL Hopkins
Nature Biotechnology 25 (10), 1110-1111, 2007
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis, RM Rodriguiz, XP Huang, ...
Nature 492 (7428), 215-220, 2012
Can we rationally design promiscuous drugs?
AL Hopkins, JS Mason, JP Overington
Current opinion in structural biology 16 (1), 127-136, 2006
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors
AL Hopkins, J Ren, RM Esnouf, BE Willcox, EY Jones, C Ross, ...
Journal of medicinal chemistry 39 (8), 1589-1600, 1996
Multiplexed SNP genotyping using the Qbead system: a quantum dot‐encoded microsphere‐based assay
H Xu, MY Sha, EY Wong, J Uphoff, Y Xu, JA Treadway, A Truong, ...
Nucleic Acids Research 31 (8), e43-e43, 2003
Genomic-scale prioritization of drug targets: the TDR Targets database
F AgŁero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ...
Nature reviews Drug discovery 7 (11), 900-907, 2008
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this†…
RM Esnouf, J Ren, AL Hopkins, CK Ross, EY Jones, DK Stammers, ...
Proceedings of the National Academy of Sciences 94 (8), 3984-3989, 1997
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design
J Ren, R Esnouf, A Hopkins, C Ross, Y Jones, D Stammers, D Stuart
Structure 3 (9), 915-926, 1995
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants
AL Hopkins, J Ren, H Tanaka, M Baba, M Okamato, DI Stuart, ...
Journal of medicinal chemistry 42 (22), 4500-4505, 1999
Fragment screening by surface plasmon resonance
I Navratilova, AL Hopkins
ACS Medicinal Chemistry Letters 1 (1), 44-48, 2010
Predicting promiscuity
AL Hopkins
Nature 462 (7270), 167-168, 2009
Crystal Structures of HIV-1 Reverse Transcriptase in Complex with Carboxanilide Derivatives,
J Ren, RM Esnouf, AL Hopkins, J Warren, J Balzarini, DI Stuart, ...
Biochemistry 37 (41), 14394-14403, 1998
The system can't perform the operation now. Try again later.
Articles 1–20